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Abstract
Background: We previously demonstrated that hyperglycemia could suppress apolipoprotein M (apoM) synthesis
both in vivo and in vitro; however, the mechanism of hyperglycemia-induced downregulation of apoM expression is
unknown yet.
Methods: In the present study we further examined if hexosamine pathway, one of the most important pathways
of glucose turnover, being involved in modulating apoM expression in the hyperglycemia condition. We examined
the effect of glucosamine, a prominent component of hexosamine pathway and intracellular mediator of insulin
resistance, on apoM expression in HepG2 cells and in rat’s models. In the present study we also determined
apolipoprotein A1 (apoA1) as a control gene.
Results: Our results demonstrated that glucosamine could even up-regulate both apoM and apoA1 expressions in
HepG2 cell cultures. The glucosamine induced upregulation of apoM expression could be blocked by addition of
azaserine, an inhibitor of hexosamine pathway. Moreover, intravenous infusion of glucosamine could enhance
hepatic apoM expression in rats, although serum apoM levels were not significantly influences.
Conclusions: It is concluded that both exogenous and endogenous glucosamine were essential for the over-
expression of apoM, which may suggest that the increased intracellular content of glucosamine does not be
responsible for the depressed apoM expression at hyperglycemia condition.
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Introduction
Apolipoprotein M, discovered by Ning Xu and Dahlbäck in
1999, is mainly located in high-density lipoprotein (HDL)
in the blood [1]. By influencing preβ-HDL formation and
cholesterol efflux, apoM is thought to be an important
regulative factor in HDL metabolism and further affects on
the initiation and development of atherosclerosis [2].
ApoM, in vivo, could be function as an acceptor of
sphingosine- 1-phosphate and could enhance HDL-
mediated anti-oxidation effects [3, 4]. It has been sug-
gested that apoM may associate with coronary heart disease
(CHD), diabetes and other diseases with dyslipidemia [5].
The serum apoM concentration is significantly reduced in
diabetic patients [6]. Single nucleotide polymorphism
(SNP) T-778C, C-724del and T-855C in the proximal
promoter region of apoM gene have significant associ-
ations with CAD and type-2 diabetes among Han
Chinese [7, 8]. Moreover, apoM is reduced in diabetic rats
and exogenous insulin administrations could partially re-
verse the abnormal apoM expression [9]. Intralipid could
increase plasma FFA levels in rats, decrease insulin sensitiv-
ity and suppressed apoM expression [10]. Whereas in our
cell culture experiments, insulin, insulin-like growth
factor I (IGF-I) and IGF-I potential peptide (IGF-IPP)
could significantly inhibit apoM expression in a dose-
and a time-dependent manner [11]. The mechanism of
this discrepancy of experimental result in vivo and in vitro
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is still unknown. We previously reported that hypergly-
cemia could significantly down-regulate apoM expression
either in vivo or in vitro [12], which could be reversed by
rosiglitazone in vivo [13], but it’s mechanism is unknown
yet. Hyperglycemia could stimulate the hexosamine path-
way and leads to the increase of the endogenous glucosa-
mine and metabolites of glycosylation [14]. In the present
we investigated if glucosamine, a common subject of
hexosamine biosynthesis pathway,being responsible for
hyperglycemia-induced suppression of apoM expression.
Result
Effects of glucosamine on the expressions of apoM and
apoA1 in HepG2 cells
In HepG2 cell cultures, the mRNA levels of apoM and
apoA1 were significantly increased in the presence of glu-
cosamine compared to the group without glucosamine
(control group), with a dose-dependent manner (Fig. 1a).
As shown in Fig. 1b, the cells cultured with azaserine alone,
cells cultured with glucosamine alone and cells cultured
with glucosamine together with azaserine, the apoM
mRNA was decreased by about 32 % when cells cul-
tured with azaserine alone compared to the control
group (P < 0.01), which indicates that azaserine itself
could inhibit apoM expression in HepG2 cells. The
apoM mRNA levels were significantly increased when
the cells cultured with glucosamine alone, whereas
when the cells cultured with glucosamine in the pres-
ence of azaserine the apoM mRNA levels were much
lower compared to the cells cultured with glucosamine
alone.
Effects of short-term glucosamine infusion on apoM
synthesis and lipids profile in rats
When rats were infused with saline (control group) or with
glucosamine at 1 mmol/L or 10 mmol/L for 6 h, the mean
concentration of serum glucosamine was about 0.04 mmol/
L, 0.3 mmol/L, and 1.71 mmol/L respectively. The hepatic
apoM mRNA levels were increased by 3.8 fold in rats
infused with glucosamine at 1 mmol/L and by 8.6 fold
when rats infused with glucosamine at 10 mmol/L com-
pared to the rats infused with saline (Fig. 2a), while the
serum apoM levels were not statistically different between
these groups (Fig. 2b). As shown in Fig. 3a and b, there
were no statistical significant changes on serum glucose, in-
sulin, triglycerides and cholesterol levels when rats infused
with wither glucosamine or saline. The serum HDLs were
slightly increased by 4.6 % when rats infused with 1 mM
glucosamine and increased by 27.7 % when rats infused
with 10 mM glucosamine. The serum levels of LDL and
lipoprotein a (Lpa) were slightly decreased in rats infused
with 1 mM and 10 mM glucosamine compared to the con-
trol rats, but there was no statistical significance due to
large individual variance (Fig. 3c).
Discussion
ApoM may play an important role in HDL-mediated
cholesterol reverse transport and is an attractive target for
the treatment of diabetes, obesity, hyperinsulinemia and
dyslipidemia [1, 2]. Hyperglycemia was shown to down-
regulate the expression of apoM in vivo and in vitro [12],
but the mechanism was still unknown. It has been reported
that hyperglycemia could increase hexosamine biosynthesis
pathway flux [15]. The hexosamine pathway constitutes a




































































































Fig. 1 Effects of glucosamine on mRNA levels of apoM and ApoA1in
HepG2 cells HepG2 cells were cultured with different concentrations
of glucosamine (panel a) with or without azaserine (Panel b) for 24 h.
In panel A, the mRNA levels of apoM and apoA1 were determined by
real-time RT-PCR. In panel B, glucosamine was at 5 mmol/L and azaserine
was at 5 μmol/L. The apoM mRNA levels were determined by real-time
RT-PCR. Each experimental group contained 6 replicates and real-time
RT-PCRs were run in triplicate. The control group is set 100 %. *P <0.05
and **P <0.01 vs. control group
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regulation of glucose homeostasis [16]. Glucosamine is a
prominent component of the hexosamine pathway and it
has many physiological functions [17, 18]. The increased
glucosamine via the hexosamine biosynthesis pathway im-
pairs glucose transport and insulin action mediated by al-
tered gene expression, and then changed the metabolism
of glucose and lipoproteins [19]. We hypothesized that
hyperglycemia induced down-regulation of apoM expres-
sion may mediate via the glucosamine pathway. Contrary
to our hypothesis, the present results demonstrated an
obvious up-regulative effect of glucosamine on apoM ex-
pression in vivo and in vitro.
In mammalian cells, under normal conditions, hexo-
samine pathway diverts 2–5 % of the fructose-6-phosphate
derived from glucose into glucosamine-6-phosphate
(GlcN-6-P), thus giving rise to obligatory substrates for the
synthesis of glycoproteins and glycolipids [20]. Exogenous
glucosamine is phosphorylated by hexokinases to
GlucN-6-P after its entry into the cells. Endogenous
GlucN-6-P is formed by fructose-6-P and glutamine by
GFAT, which is the rate-limiting enzyme in the hexosa-
mine pathway [21]. When the HepG2 cells were
treated with azaserine, the inhibitor of GFAT, the en-
dogenous hexosamine pathway was inhibited and the
expression of apoM was suppressed significantly.
When treated with glucosamine, the hexosamine path-
way was continued by exogenous substrate and apoM
mRNA was increased greatly. The results suggested
Fig. 2 Effects of glucosamine on apoM synthesis in rats. Hepatic apoM
mRNA levels (Panel a) were determined by real-time RT-PCR. Serum
apoM levels (Panel b) were determined by Western-blot analysis
as described in Materials and methods. A sample of Western-blot
analysis is represented in panel c. The control group is set as 100 %.
*P <0.05 and **P< 0.01 vs. control
Fig. 3 Effects of glucosamine on glucose, insulin, lipids and lipoproteins
in rats. Serum glucose was measured by the glucose oxidase method.
Insulin was measured by radioimmunoassay (Panel a). Total cholesterol,
triglycerides (Panel b) and HDL-cholesterol, LDL-cholesterol and
lipoprotein a (Panel c) were measured by standard clinical chemistry
methods. The control group is set 100 %. *P <0.05 and **P< 0.01
vs. control
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both exogenous and endogenous hexosamine pathway
being essential for the expression of apoM.
In the present study, there were no statistical signifi-
cant changes on serum glucose and insulin levels after
administration of glucosamine in rats. This may explain the
different animal models used and short-term glucosamine
infused in rats in the present study. It has been reported
that the serum concentration of glucosamine is only about
0.0-0.04 mmol/L in the healthy people. After supplement
of 30 g glucosamine intravenously, the serum concentra-
tion of glucosamine could be reach level of 1.42 mmol/L,
however, it didn’t influence insulin sensitivity [22, 23]. In
certain metabolic studies, after glucosamine administra-
tion orally or intravenously, could not demonstrate a sig-
nificant change on blood concentrations of glucose or
insulin [17, 24, 25].
Previous studies demonstrated that glucosamine could
attenuate the vessel injury induced by hyperglycemia, pro-
mote apolipoprotein A1 expression and impair hepatic
apolipoprotein B100 (apoB100) assembly and secretion
[19, 26–28]. In this study, we confirmed that glucosamine
enhanced apoM expression and both exogenous and en-
dogenous glucosamine might be essential for the expres-
sion of apoM. It appeared that the increased intracellular
content of glucosamine, a known mediator of insulin resist-
ance, not be responsible for the reduced apoM expression
in hyperglycemia condition. Moreover, the present study
may open a new sight into the pathophysiological proced-
ure of the apoM and apoM overexpression for a potential
role on improving lipoprotein metabolism in vivo, which
could be considered as a future therapeutic target against
insulin resistance and type-2 diabetes.
Conclusion
ApoM expression could be up-regulated by glucosamine
in vivo and in vitro. Both exogenous and endogenous
glucosamine are essential for the expression of apoM.
Hyperglycemia induced down-regulation of apolipopro-
tein M expression is not via the hexosamine pathway.
Materials and methods
Materials
The established hepatoblastoma cell line, HepG2 cells,
was from American Type Culture Collection (Manassas,
VA, USA). Six-well cell culture clusters and 25-cm2
vented cell culture flasks were purchased from Gibco.
Cell culture media were from the Gibco. Real-time
RT-PCR reagents and control probe GAPDH andβ-
actin were purchased from Shanghai Shenergy Biotech
Co. Ltd. RevertAidTM First Strand cDNA Synthesis
Kit was purchased from Fermenta. Glucosamine and
azaserine were from Sigma. Rat fix-container was
obtained from Beijing Xinhang Company (Beijing,
China). Intravenous catheter was purchased from
Becton Dickinson Medical Devices Co. Ltd. (Suzhou,
China). Microinfusion pumps were purchased from
Zhejiang University (Zhejiang, China).
Cell cultures
HepG2 cells were cultured in 25-cm2 vented flasks con-
taining DMEM with 10 % fetal calf serum (FCS) in the
presence of benzyl-penicillin (100 U/ml) and streptomycin
(100 μg/ml) under standard culture conditions (5 % CO2,
37 °C). Cells were seeded in six-well cell culture clusters,
and were grown to 50–70 % confluence. Prior to experi-
ment, cells were washed twice with phosphate buffered
saline (PBS) and once with serum-free DMEM without
antibiotic. Experimental medium contained DMEM with
0.5 % bovine serum albumin (BSA) and different concen-
trations of glucosamine and/or azaserine were added as
specified in the legend to figures.
Animal experiments
All the animal work was conducted in the compliance
with the recommendations on the guide for the care and
use of laboratory animals, and approved by the local ethic
committee. Healthy adult male SD rats (body weight at
180–205 g) were obtained from Shanghai Slac Laboratory
Animal Co. (Shanghai, China), and were kept in separated
cages in a temperature-controlled (22 °C) room with 12-h
light–dark cycle. Animals were provided with standard
rodent chow and water ad libitum, and were acclimatized
for 1 week before experiments. Rats were randomly di-
vided into three groups five rats per group). All rats were
deprived of food for 12 h before experiments. Animals
were fixed on a special restraining-container and catheters
were inserted into the tail vein. Rats were continuously in-
fused (2.5 ml/h) with either 1 mmol/L glucosamine,
10 mmol/L glucosamine or 0.9 % saline (control group),
respectively, by microinfusion pumps. After 6 h, rats were
anesthetized and sacrificed. Blood samples were taken
through inferior vena cava and the serum was separated
and frozen at −70 °C. A specimen of liver tissue was sec-
tioned and stored in liquid nitrogen.
Measurement of plasma apoM levels
Serum apoM concentration was assayed by Western-blot
analysis with a specific polyclonal rabbit anti recombinant
human apoM antibody. In brief, serum was diluted with
PBS buffer (1:20) and 20 μl diluted samples were frac-
tionated by SDS–polyacrylamide gel electrophoresis
(SDS–PAGE), transferred to nitrocellulose membrane,
and incubated with rabbit anti recombination human
apoM polyclonal antibodies. Horseradish peroxidase-
conjugated swine anti-rabbit IgG were used as the sec-
ondary antibody. Bands corresponding to the apoM
were visualized by an ECL + Plus Western blotting
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detection system (Amersham) . The relative amount of
apoM was analyzed with Bio-Rad computer using
Quantity One software.
Total RNA extraction and real-time PCR
Total RNA of HepG2 cells and rat liver tissues were iso-
lated by Trizol method, and sequentially reverted to
cDNA according to the manufacturer’s instruction. Primer
5.0 Software was used to design rat and human apoM
primers and probe used in the TaqMan assay. The rat and
human apoM primers and probes were shown in Table 1.
Relative standard curves for apoM, GAPDH and β-actin
were performed to compensate the efficiency of PCR. A
serial dilution of apoM cDNA was used to generate a
standard curve by plotting the cycle threshold versus the
log of input cDNA. Relative quantitative of mRNA was
performed on Lightcycle. PCR of apoM was carried out in
a 25ul reaction mixture containing 10 pmol of both for-
ward and reverse primers, 10 pmol probe, 5 nmol dNTP,
2.5U Taq polymerase and 2ul cDNA. The mixture was
preheated for 5 min to activate Taq polymerase. Then a
40-cycle two-step PCR was performed consisting of 5 s at
95 °C and 30 s at 60 °C. Real-time RT-PCR of GAPDH
and β-actin was performed according to the manufac-
turer’s instruction. The threshold cycle (CT) is defined as
fractional cycle number at which the reporter fluorescence
reaches a certain level.
Chemical measurement
Blood glucose was measured by the glucose oxidase
method. Insulin was measured by radioimmunoassay
(Beijing Atom Hightech Co, China). Serum glucosa-
mine, total cholesterol, triglycerides, HDL-cholesterol
and LDL-cholesterol were measured by standard clin-
ical chemistry methods.
Statistics
Statistical analyses were performed with the Prism on an
Apple computer. Comparisons among groups were statisti-
cally analyzed by one-way ANOVA followed by unpaired
Student’s t-test or analyzed by two-tailed Mann–Whitney
U test. A P value less than 0.05 was considered as statisti-
cally significant.
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